AR049126A1 - Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing. - Google Patents
Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing.Info
- Publication number
- AR049126A1 AR049126A1 ARP050102199A ARP050102199A AR049126A1 AR 049126 A1 AR049126 A1 AR 049126A1 AR P050102199 A ARP050102199 A AR P050102199A AR P050102199 A ARP050102199 A AR P050102199A AR 049126 A1 AR049126 A1 AR 049126A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterocyclyl
- alkoxycarbonyl
- alkoxy
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Composiciones farmacéuticas que los contienen y su uso en la fabricacion de medicamentos con actividad inhibidora de aldosterona sintasa para el tratamiento y prevencion del síndrome de Cushing, hipocalemia, hipertension, hiperaldosterismo primario y secundario y enfermedades relacionadas. Reivindicacion 1: Un compuesto de formula general (1) en el que X es N; Y es C; Z es un enlace; R a) es H; o b) es alquilo C1-8, alcoxi C1-8, halogeno o trifluorometilo; R1 es alquilo C1-8, alquenilo C2-8, alquinilo C2-8, aril-alquilo C0-4 o heterociclil C0-4 insaturado, cuyos radicales no están sustituidos o están sustituidos por 1-4 alcoxi C1-8, alcoxi C1-8carbonilo, alquilo C1-8, alquilcarbonilo C0-8, alquilsulfonilo C1-8, aril-alcoxi C0-4- carbonilo, arilo, ciano, halogeno, heterociclilo, oxo, trifluorometoxi, trifluorometilo o tri-alquil C1-4 sililo; R2 a) es H; o b) es alquilo C1-8, cicloalquilo C3-8, halogeno, carboxi-alquilo C1-4, alcoxicarbonilo C1-4-alquilo,C1-4 alquilcarbonilo C0- 4, aril-alquilo C0-4 o heterociclil-alquilo C1-4 insaturado, cuyos radicales no están sustituidos o están sustituidos por 1-4 alcoxi C1-8, alcoxi C1-8carbonilo, alquilo C1-8, alquilcarbonilo C0-8, alquilsulfonilo C1-8, aril-alcoxi C0-4- carbonilo, arilo, ciano, halogeno, heterociclilo, oxo, trifluorometoxi, trifluorometilo, o tri-alquil C1-4 sililo; n es un numero 0, 1 o 2; y su sal, profármaco o compuesto en los que uno o más átomos están reemplazados por sus isotopos estables, no radiactivos, en particular sal util desde el punto de vista farmacéutico, donde si R2 es H, R1 no es naftilo o carbazolilo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH9152004 | 2004-05-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR049126A1 true AR049126A1 (es) | 2006-06-28 |
Family
ID=34968588
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050102196A AR049125A1 (es) | 2004-05-28 | 2005-05-27 | Heterociclos biciclicos nitrogenados inhibidores de la aromatasa. |
ARP050102199A AR049126A1 (es) | 2004-05-28 | 2005-05-27 | Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050102196A AR049125A1 (es) | 2004-05-28 | 2005-05-27 | Heterociclos biciclicos nitrogenados inhibidores de la aromatasa. |
Country Status (10)
Country | Link |
---|---|
US (2) | US8680079B2 (es) |
EP (2) | EP1765777A2 (es) |
JP (2) | JP5179174B2 (es) |
CN (2) | CN1960991A (es) |
AR (2) | AR049125A1 (es) |
BR (2) | BRPI0511621A (es) |
CA (2) | CA2568159A1 (es) |
IL (2) | IL179408A0 (es) |
TW (2) | TW200616623A (es) |
WO (2) | WO2005118540A2 (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8680079B2 (en) * | 2004-05-28 | 2014-03-25 | Novartis Ag | Tetrahydro-imidazo [1,5-A] pyridyin derivatives as aldosterone synthase inhibitors |
TW200617010A (en) * | 2004-07-09 | 2006-06-01 | Speedel Experimenta Ag | Organic compounds |
AR056888A1 (es) * | 2005-12-09 | 2007-10-31 | Speedel Experimenta Ag | Derivados de heterociclil imidazol |
TW200804284A (en) * | 2006-03-31 | 2008-01-16 | Speedel Experimenta Ag | Process for preparing 6,7-dihydro-5H-imidazo[1,5-a]pyridin-8-one |
EP1842543A1 (en) | 2006-04-05 | 2007-10-10 | Speedel Pharma AG | Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist |
TW200808813A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
TW200808812A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
TW200813071A (en) | 2006-04-12 | 2008-03-16 | Speedel Experimenta Ag | Spiro-imidazo compounds |
DK2319923T3 (en) * | 2008-07-24 | 2014-02-24 | Meiji Seika Pharma Co Ltd | A PYRIPYROPEN biosynthetic genes |
GB2477256B (en) * | 2008-11-07 | 2013-12-25 | Univ Sheffield | Determination of predisposition towards subclinical Cushing's syndrome or incidentaloma |
MX2011011414A (es) | 2009-05-13 | 2011-12-06 | Meiji Seika Pharma Co Ltd | Proceso para producir derivados de piripiropeno. |
MX2011012627A (es) | 2009-05-28 | 2011-12-14 | Novartis Ag | Derivados aminobutiricos sustituidos como inhibidores de nepralisina. |
AU2010251967B9 (en) | 2009-05-28 | 2014-04-03 | Novartis Ag | Substituted aminopropionic derivatives as neprilysin inhibitors |
WO2011061168A1 (en) * | 2009-11-17 | 2011-05-26 | Novartis Ag | Aryl-pyridine derivatives as aldosterone synthase inhibitors |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
UA111151C2 (uk) | 2010-03-01 | 2016-04-11 | Мейдзі Сейка Фарма Ко., Лтд. | Спосіб одержання похідних пірипіропену |
US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
ES2683350T3 (es) | 2011-07-08 | 2018-09-26 | Novartis Ag | Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos |
CN103958478B (zh) * | 2011-11-30 | 2017-08-01 | 霍夫曼-拉罗奇有限公司 | 双环二氢异喹啉‑1‑酮衍生物 |
UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
CU24330B1 (es) | 2013-02-14 | 2018-03-13 | Novartis Ag | Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral) |
EA201690282A1 (ru) | 2013-07-25 | 2016-09-30 | Новартис Аг | Биоконъюгаты синтетических апелиновых полипептидов |
JP6501775B2 (ja) | 2013-07-25 | 2019-04-17 | ノバルティス アーゲー | 心不全治療用の環状ポリペプチド |
CN105593212B (zh) * | 2013-10-17 | 2019-06-04 | 豪夫迈·罗氏有限公司 | 作为醛固酮合酶抑制剂的苯基-二氢吡啶衍生物 |
WO2015055604A1 (en) * | 2013-10-17 | 2015-04-23 | F. Hoffmann-La Roche Ag | New phenyl-dihydropyridine derivatives as aldosterone synthase inhibitors |
MX2016002762A (es) * | 2013-10-17 | 2016-05-26 | Hoffmann La Roche | Derivados de fenil-dihidropiridina como inhibidores de aldosterona sintasa. |
MA41580A (fr) | 2015-01-23 | 2017-11-29 | Novartis Ag | Conjugués d'acides gras de l'apeline synthétique présentant une demi-vie améliorée |
JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
BR112019018700A2 (pt) | 2017-03-10 | 2020-04-07 | Embera Neurotherapeutics Inc | composições farmacêuticas e seus usos |
UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
JP2022509184A (ja) | 2018-11-27 | 2022-01-20 | ノバルティス アーゲー | 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン/ケキシン9型(pcsk9)阻害剤としての環状ペプチド |
UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
US20230089867A1 (en) | 2018-11-27 | 2023-03-23 | Novartis Ag | Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder |
TW202333563A (zh) | 2021-11-12 | 2023-09-01 | 瑞士商諾華公司 | 用於治療疾病或障礙之二胺基環戊基吡啶衍生物 |
AR127698A1 (es) | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4889861A (en) * | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
US4617307A (en) * | 1984-06-20 | 1986-10-14 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
JPH0670064B2 (ja) | 1986-12-08 | 1994-09-07 | 三井石油化学工業株式会社 | 二環性イミダゾ−ル誘導体 |
GB8820730D0 (en) * | 1988-09-02 | 1988-10-05 | Erba Carlo Spa | Substituted 5 6 7 8-tetrahydroimidazo/1.5-a/pyridines & process for their preparation |
US5057521A (en) | 1988-10-26 | 1991-10-15 | Ciba-Geigy Corporation | Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism |
CA2026792A1 (en) * | 1989-11-01 | 1991-05-02 | Michael N. Greco | (6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1h-benzotriazole derivatives |
WO1993015079A1 (en) * | 1992-01-27 | 1993-08-05 | Janssen Pharmaceutica N.V. | Pyrroloimidazolyl and imidazopyridinyl substituted 1h-benzimidazole derivatives as aromatase inhibitors |
US5763611A (en) * | 1992-05-29 | 1998-06-09 | The Procter & Gamble Company | Thio-substituted cyclic phosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
AU6015796A (en) * | 1995-06-14 | 1997-01-15 | Yamanouchi Pharmaceutical Co., Ltd. | Fused imidazole derivatives and medicinal composition thereof |
JPH0971586A (ja) * | 1995-09-07 | 1997-03-18 | Yamanouchi Pharmaceut Co Ltd | 新規な二環性縮合イミダゾール誘導体 |
US6333335B1 (en) * | 1999-07-23 | 2001-12-25 | Merck & Co., Inc. | Phenyl-protein transferase inhibitors |
JP2001151696A (ja) * | 1999-11-22 | 2001-06-05 | Keiko Tanaka | アクチニジンから造る腫瘍の増殖ならびに転移抑制酵素と異質なたんぱく細胞の除去剤 |
ATE533768T1 (de) * | 2000-11-17 | 2011-12-15 | Takeda Pharmaceutical | Imidazol-derivate, ihre herstellung und ihre verwendung |
JP2008500999A (ja) * | 2004-05-28 | 2008-01-17 | シュペーデル・エクスペリメンタ・アーゲー | 複素環式化合物およびアルドステロンシンターゼ阻害薬としてのそれらの使用 |
US8680079B2 (en) * | 2004-05-28 | 2014-03-25 | Novartis Ag | Tetrahydro-imidazo [1,5-A] pyridyin derivatives as aldosterone synthase inhibitors |
AR049388A1 (es) * | 2004-05-28 | 2006-07-26 | Speedel Experimenta Ag | Heterociclos como inhibidores de aldosterona sintasa |
TW200716634A (en) * | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
TW200716105A (en) * | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Imidazole compounds |
TW200813071A (en) * | 2006-04-12 | 2008-03-16 | Speedel Experimenta Ag | Spiro-imidazo compounds |
TW200808813A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
TW200808812A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
-
2005
- 2005-05-27 US US11/597,623 patent/US8680079B2/en not_active Expired - Fee Related
- 2005-05-27 AR ARP050102196A patent/AR049125A1/es unknown
- 2005-05-27 CN CNA2005800173175A patent/CN1960991A/zh active Pending
- 2005-05-27 JP JP2007513942A patent/JP5179174B2/ja not_active Expired - Fee Related
- 2005-05-27 CN CNA2005800170603A patent/CN1968930A/zh active Pending
- 2005-05-27 AR ARP050102199A patent/AR049126A1/es unknown
- 2005-05-27 EP EP05747969A patent/EP1765777A2/en not_active Withdrawn
- 2005-05-27 TW TW094117480A patent/TW200616623A/zh unknown
- 2005-05-27 BR BRPI0511621-0A patent/BRPI0511621A/pt not_active IP Right Cessation
- 2005-05-27 JP JP2007513939A patent/JP2008500997A/ja active Pending
- 2005-05-27 WO PCT/EP2005/052416 patent/WO2005118540A2/en not_active Application Discontinuation
- 2005-05-27 BR BRPI0510409-2A patent/BRPI0510409A/pt not_active IP Right Cessation
- 2005-05-27 CA CA002568159A patent/CA2568159A1/en not_active Abandoned
- 2005-05-27 WO PCT/EP2005/052419 patent/WO2005118581A1/en not_active Application Discontinuation
- 2005-05-27 TW TW094117477A patent/TW200612947A/zh unknown
- 2005-05-27 US US11/597,585 patent/US20080076784A1/en not_active Abandoned
- 2005-05-27 EP EP05752767A patent/EP1749005A1/en not_active Withdrawn
- 2005-05-27 CA CA002568163A patent/CA2568163A1/en not_active Abandoned
-
2006
- 2006-11-20 IL IL179408A patent/IL179408A0/en unknown
- 2006-11-20 IL IL179406A patent/IL179406A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20080076784A1 (en) | 2008-03-27 |
BRPI0510409A (pt) | 2007-10-23 |
IL179406A0 (en) | 2007-05-15 |
JP2008501000A (ja) | 2008-01-17 |
CN1968930A (zh) | 2007-05-23 |
JP2008500997A (ja) | 2008-01-17 |
US8680079B2 (en) | 2014-03-25 |
CA2568159A1 (en) | 2005-12-15 |
EP1749005A1 (en) | 2007-02-07 |
AR049125A1 (es) | 2006-06-28 |
WO2005118540A3 (en) | 2006-02-02 |
WO2005118581A1 (en) | 2005-12-15 |
JP5179174B2 (ja) | 2013-04-10 |
CN1960991A (zh) | 2007-05-09 |
WO2005118540A2 (en) | 2005-12-15 |
EP1765777A2 (en) | 2007-03-28 |
TW200616623A (en) | 2006-06-01 |
IL179408A0 (en) | 2007-05-15 |
CA2568163A1 (en) | 2005-12-15 |
US20070225232A1 (en) | 2007-09-27 |
BRPI0511621A (pt) | 2008-01-02 |
TW200612947A (en) | 2006-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR049126A1 (es) | Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing. | |
AR049711A1 (es) | Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso | |
AR111425A2 (es) | MODULADORES SELECTIVOS DE RECEPTORES DE ANDRÓGENOS (SARMs) Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN | |
AR050208A1 (es) | Compuesto de heteroaril sulfonamida sustituida, procedimiento para la preparacion del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento | |
AR049388A1 (es) | Heterociclos como inhibidores de aldosterona sintasa | |
AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
SE0402735D0 (sv) | Novel compounds | |
AR054129A1 (es) | Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7 | |
UY30183A1 (es) | Derivados de quinolina | |
AR051997A1 (es) | Heterociclos triciclicos, su obtencion y uso delos mismos c omo agentes farmaceuticos | |
NI200700102A (es) | Derivados de indol tetraciclicos como agentes antiviricos | |
AR032361A1 (es) | Derivados de androstano y sales y solvatos de los mismos, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que comprenden tales compuestos, proceso para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de tales compuestos | |
GT200500307A (es) | Compuestos quimicos | |
AR056888A1 (es) | Derivados de heterociclil imidazol | |
AR072791A1 (es) | DERIVADOS DE TIAZOLIDIN-2, 4-DIONA, MÉTODOS PARA SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE Y SU USO EN LA ELABORACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER. | |
EA200802007A1 (ru) | Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине | |
UY27714A1 (es) | 2 - heteroaril - pirimidinas inhibidoras de cdk, su preparación y su uso como medicamentos. | |
AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
AR077478A2 (es) | Derivados de oxindol sustituido medicamentos que los comprenden y uso de los mismos | |
UY29266A1 (es) | Compuestos de piridazinona | |
AR060590A1 (es) | Compuestos imidazo | |
AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
UY31254A1 (es) | Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones | |
GT200600161A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |